Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 11,331 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Alopecia Areata
Interventions: PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more

Conditions: Sarcoma, Soft Tissue
Interventions: Observational Only - Transcutaneous Oxygen Measurement; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Gainesville, Florida • Iowa City, Iowa • Cleveland, Ohio + 1 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more

Conditions: Malignant Melanoma
Interventions: HSPPC-96 or Oncophage; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more

Conditions: Heart Failure
Interventions: ivabradine, Usual Care; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 20
States / cities: Aurora, Colorado • Fort Lauderdale, Florida • Athens, Georgia + 17 more

Conditions: Stroke, Acute, Stroke, Hemiparesis
Interventions: NMES device with EMG-triggered and Cyclic capabilities; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Akron, Ohio • Cincinnati, Ohio • Cleveland, Ohio

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 502
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 349 more

Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions: Stool tests; Procedure
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more

Conditions: Alzheimer's Disease
Interventions: T-817MA-H, T-817MA-L, Placebo; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 50
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more

Conditions: Rett Syndrome
Interventions: Intravenous infusion; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 5 Years to 25 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myelopathy, Compressive, Radiculopathy, Cervical, C5 Palsy
Interventions: Bilateral Cervical Keyhole Foraminotomy, Cervical Decompression; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Asthma
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Interventions: Infigratinib, Placebo; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 47
States / cities: Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more

Conditions: Alpha 1 Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-PI; Drug · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more

Conditions: Endometrial Cancer
Interventions: Selinexor, Matching Placebo for selinexor; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 55 more

Conditions: Short Bowel Syndrome
Interventions: Crofelemer Oral Product; Drug
Lead sponsor: Jessica Sosio; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aortic Aneurysm, Aortic Dissection, Aortic Rupture
Interventions: Thoraflex™ Hybrid Device; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Spinal Cord Injury Cervical, Spinal Cord Injuries (Complete and Incomplete)
Interventions: Brain Computer Interface (BCI) - Functional Electrical Stimulation (FES) system; Device
Lead sponsor: Case Western Reserve University; Other
Eligibility: 22 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Malignant Neoplasm of Breast
Interventions: Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire; Procedure · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Thrombosis, Pediatrics
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more

Conditions: Colorectal Neoplasms
Interventions: Regorafenib (BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
U.S. locations: 62
States / cities: Duarte, California • La Jolla, California • Long Beach, California + 53 more

Conditions: Lupus Erythematosus, Systemic
Interventions: PF-04236921; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 68
States / cities: Anniston, Alabama • Birmingham, Alabama • Fair Oaks, California + 42 more

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 15 more

Search by objective public record fields.

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Colorectal Cancer Screening in Cystic Fibrosis

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome

Can Prophylactic Foraminotomy Prevent C5 Palsy

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Thoraflex™ Hybrid IDE Study

Development of Optimal Sensory Feedback Strategies to Maximize Function After Tetraplegia

Breast Reconstruction Following Breast Cancer in Very High Risk Patients

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)